Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that it is commencing an underwritten public offering of $250.0 million of its common stock. In addition, Arvinas intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $37.5 million of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by Arvinas.

Arvinas, Inc. Announces Proposed Offering of Common Stock

The stock price of Arvinas Inc (NASDAQ: ARVN) doubled from $29.93 in the previous close to $60.60 as of 2:09 PM. This is why it happened.

Arvinas Stock Price Doubled Today: Why It Happened

AnPac Bio-Medical Science Co

Aerpio Pharmaceuticals Inc

Synlogic

Veru

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.

5 Biopharma Stocks Making Big Moves Monday

Arvinas (ARVN) news for Monday includes positive interim results from clinical trials sending ARVN stock soaring to new highs. The post Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today appeared first on InvestorPlace.

Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population –

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET –

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced platform updates and disclosed five additional programs from its preclinical pipeline. Arvinas’ portfolio encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience.

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020. The presentation will reflect on Arvinas’ advances in its PROTAC® platform and introduce new pipeline programs.

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

NEW HAVEN, Conn., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

NEW HAVEN, Conn., Aug.  07, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11 at 10:20 a.m. ET.

Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference

NEW HAVEN, Conn., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to Decline

NEW HAVEN, Conn., June  29, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors. Dr. Dixon is a well-respected leader with 40 years of broad and deep experience in the biopharmaceutical industry, including a strong track record of successful product launches.

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

NEW HAVEN, Conn., June  17, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 8:30 a.m. ET.

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., June  11, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain has joined its Board of Directors. Ms. Bain, who is currently the Chief Financial Officer of Codiak BioSciences, Inc., is an experienced business and financial leader with a strong track record of driving results, accelerating growth, and building shareholder value.  

Arvinas Appoints Linda Bain to its Board of Directors

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

Allogene Therapeutics Inc

Amgen

CytomX Therapeutics

MacroGenics

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

5 ASCO Abstracts Moving Biopharma Stocks

Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.

Here's Why Arvinas Shares Are Tumbling 13.7% Today

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality -

Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Arvinas (ARVN) Stock Stands Out in a Strong Industry

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know

Shares of Arvinas (NASDAQ:ARVN) rose 1.5% after the company reported Q1 results.

Recap: Arvinas Q1 Earnings

NEW HAVEN, Conn., April  13, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity, including clinical trials, supply chain, and discovery research.

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

NEW HAVEN, Conn., March  31, 2020  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the acceptance of an abstract for presentation at the American Society of Clinical Oncology (ASCO) annual meeting being held virtually May 29 - June 2, 2020. The presentation will include updated clinical data from the Arvinas’ Phase 1 dose escalation trial of ARV-110.  

News for Arvinas Inc Stock (ARVN)